Harbor Capital Advisors Inc. Reduces Stock Holdings in Encompass Health Co. (NYSE:EHC)

Harbor Capital Advisors Inc. trimmed its holdings in shares of Encompass Health Co. (NYSE:EHC) by 0.9% during the 4th quarter, Holdings Channel reports. The institutional investor owned 72,627 shares of the company’s stock after selling 645 shares during the period. Harbor Capital Advisors Inc.’s holdings in Encompass Health were worth $6,707,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. TD Private Client Wealth LLC grew its stake in Encompass Health by 2,870.0% during the 3rd quarter. TD Private Client Wealth LLC now owns 7,336 shares of the company’s stock valued at $709,000 after purchasing an additional 7,089 shares during the last quarter. Los Angeles Capital Management LLC grew its stake in Encompass Health by 532.4% during the 3rd quarter. Los Angeles Capital Management LLC now owns 50,290 shares of the company’s stock valued at $4,860,000 after purchasing an additional 42,338 shares during the last quarter. Pathstone Holdings LLC grew its stake in Encompass Health by 54.5% during the 3rd quarter. Pathstone Holdings LLC now owns 21,022 shares of the company’s stock valued at $2,032,000 after purchasing an additional 7,412 shares during the last quarter. Deerfield Management Company L.P. Series C purchased a new stake in shares of Encompass Health in the second quarter worth about $541,000. Finally, Meeder Asset Management Inc. boosted its stake in shares of Encompass Health by 43.8% in the third quarter. Meeder Asset Management Inc. now owns 66,405 shares of the company’s stock worth $6,417,000 after buying an additional 20,242 shares during the last quarter. 97.25% of the stock is currently owned by hedge funds and other institutional investors.

Encompass Health Stock Down 1.2 %

Shares of NYSE EHC traded down $1.08 during mid-day trading on Friday, hitting $91.76. The company had a trading volume of 126,768 shares, compared to its average volume of 591,432. The company has a market capitalization of $9.24 billion, a PE ratio of 22.16, a price-to-earnings-growth ratio of 1.30 and a beta of 0.89. The company has a debt-to-equity ratio of 0.88, a current ratio of 1.04 and a quick ratio of 1.04. Encompass Health Co. has a 1-year low of $67.94 and a 1-year high of $104.55. The business’s 50-day simple moving average is $98.39 and its 200 day simple moving average is $93.61.

Encompass Health (NYSE:EHC) last announced its quarterly earnings data on Monday, October 28th. The company reported $1.03 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.94 by $0.09. Encompass Health had a return on equity of 17.60% and a net margin of 8.10%. The business had revenue of $1.35 billion for the quarter, compared to analysts’ expectations of $1.33 billion. During the same period last year, the firm earned $0.86 earnings per share. The company’s revenue for the quarter was up 11.9% compared to the same quarter last year. On average, analysts predict that Encompass Health Co. will post 4.29 earnings per share for the current year.

Encompass Health Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Wednesday, January 15th. Shareholders of record on Thursday, January 2nd will be paid a $0.17 dividend. This represents a $0.68 dividend on an annualized basis and a yield of 0.74%. The ex-dividend date is Thursday, January 2nd. Encompass Health’s dividend payout ratio is presently 16.43%.

Wall Street Analyst Weigh In

EHC has been the subject of a number of analyst reports. Barclays upped their price target on Encompass Health from $109.00 to $116.00 and gave the stock an “overweight” rating in a report on Tuesday, October 29th. Truist Financial reaffirmed a “buy” rating and issued a $116.00 price target (up previously from $108.00) on shares of Encompass Health in a report on Wednesday, October 30th. Royal Bank of Canada upped their price target on Encompass Health from $105.00 to $110.00 and gave the company an “outperform” rating in a research report on Wednesday, October 30th. KeyCorp upped their price target on Encompass Health from $115.00 to $117.00 and gave the company an “overweight” rating in a research report on Tuesday, October 29th. Finally, UBS Group upped their price target on Encompass Health from $100.00 to $110.00 and gave the company a “buy” rating in a research report on Wednesday, September 25th. Nine investment analysts have rated the stock with a buy rating and two have issued a strong buy rating to the company. According to data from MarketBeat.com, Encompass Health presently has a consensus rating of “Buy” and a consensus price target of $107.11.

Encompass Health Company Profile

Encompass Health Corporation provides post-acute healthcare services in the United States and Puerto Rico. It owns and operates inpatient rehabilitation hospitals that provide medical, nursing, therapy, and ancillary services. The company provides specialized rehabilitative treatment on an inpatient basis to patients who have experienced physical or cognitive disabilities or injuries due to medical conditions, such as strokes, hip fractures, and various debilitating neurological conditions.